JMJelena Mirkovic

Jelena Mirkovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jelena Mirkovic has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mesonephric and Mesonephric-Like Proliferations of the Gynecologic Tract

    by Lawrence Hsu Lin, Jelena Mirkovic, Elizabeth D. Euscher

    Mesonephric remnants are vestiges of Wolffian ducts located adjacent to the Müllerian ducts. Proliferations arising from these remnants are uncommon and classified as benign, including mesonephric hyperplasia, Gartner and rete cysts, papillary cystadenoma, rete adenoma, and female adnexal tumor of probable wolffian origin (only rare cases of the latter exhibited malignant behavior), or malignant, including mesonephric adenocarcinoma and carcinosarcoma. Morphologic evaluation aided by immunohistochemistry, especially in carcinomas, is the cornerstone to establish the correct diagnosis. In contrast to mesonephric adenocarcinoma, which arises predominantly in the cervix and is frequently associated with mesonephric hyperplasia, mesonephric-like adenocarcinoma is currently considered to be a neoplasm of Müllerian derivation that undergoes transdifferentiation into a Wolffian phenotype. There is significant morphologic, immunohistochemical, genetic and epigenetic overlap between mesonephric carcinoma and mesonephric-like carcinoma. However, distinctive features are seen in each of these entities, including primary site (cervix vs. corpus/extrauterine locations), associated precursors (mesonephric remnants/hyperplasia vs. atypical endometrial hyperplasia/endometriosis/other Müllerian neoplasm), and some differences in the immunohistochemical (more frequent ER and TTF1 positivity in mesonephric-like carcinoma) and molecular profiles (mesonephric-like adenocarcinoma more frequently harbors genetic alterations reported in other Müllerian tumors, such as PIK3CA, PTEN , and CTNNB1 ). In this review, we provide a detailed overview of the clinicopathologic and molecular features of benign mesonephric proliferations, mesonephric-derived tumors, and mesonephric-like adenocarcinoma, as well as their differential diagnoses.

  • Uterine Leiomyomas Presenting During Pregnancy and Delivery

    by Ekaterina Olkhov-Mitsel, Yutaka Amemiya, Arun Seth, Carlos Parra-Herran, Jelena Mirkovic

    A subset of uterine leiomyomas becomes clinically apparent during pregnancy/delivery and is typically excised during Cesarean section. Although benign, these leiomyomas excised during pregnancy and/or delivery (LEPs) can pose diagnostic challenges due to morphologic changes that mimic malignant mesenchymal neoplasms, such as leiomyosarcoma. This study analyzed 97 LEPs to characterize their histopathologic and immunohistochemical features. Histologic examination revealed predominantly low mitotic activity (mean: 0.5 mitoses/10 HPFs) and mild (87.6% of tumors) to at most focal moderate (9.3% of tumors) nuclear atypia. Ischemic necrosis occurred in 57.7% of tumors. Features attributed to coagulative necrosis were common, including sharp viable-nonviable transition (22.7%), perivascular tumor preservation (9.3%), and ghost outlines of tumor cell nuclei (50.5%). Focal myxoid changes, affecting ≤30% of tumor volume, were seen in 42.3% of tumors. Rare, bizarre cells were identified in 48.5% of tumors. Immunohistochemistry demonstrated the absence of estrogen receptor staining in 65% of tumors, with focal staining in 35.2%, and progesterone receptor expression in 97.7%. Caldesmon (98.9%) and desmin (100%) were positive, with the majority diffuse. CD10 (100%) showed variable staining intensity. Wild-type p53 expression was seen in all tumors tested. Expression of ATRX, MTAP, RB1, and PTEN was predominantly retained with equivocal staining in 35.3% (ATRX) and 3.4% (RB1) of tumors. Although Cyclin D1 expression was common (97.4%), it was always focal, with no diffuse (≥70%) strong nuclear staining. FH loss occurred in 3.2% of tumors. All tumors were negative for MelanA, and 92.4% were negative for HMB45. Calretinin expression was observed in 39% of tumors, typically focal and strong, while only 1 tumor showed positive inhibin staining in <5% of cells. ALK expression was focally positive or equivocal in 9.6% of cases, but no gene rearrangements were identified by in situ hybridization. Follow-up data were available for 71 patients (mean: 56 mo), with no malignant transformation or recurrence. These findings confirm that LEPs exhibit distinct morphologic and immunophenotypic alterations, including features typically attributed to coagulative tumor cell necrosis. However, given benign clinical outcomes, low mitotic activity, and lack of significant atypia, such a finding does not warrant designation as leiomyosarcoma or smooth muscle tumor of uncertain malignant potential in the context of concurrent pregnancy.

  • Open Access

    Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA Consortium

    by Anne M. Mills, Elizabeth D. Euscher, W. Glenn McCluggage, Jelena Mirkovic, Kay J. Park, David L. Kolin, Lien Hoang, Hyun-Soo Kim, Jeffrey A. How, Karen H. Lu, et al.

    Mesonephric-like adenocarcinoma (MLA) is a rare and aggressive gynecologic malignancy that has only been recognized in the last decade. It arises in the endometrium, ovaries, and other extrauterine sites (often in association with endometriosis) and closely mimics a variety of other tumor types that occur in these locations. While it shows significant morphologic, immunohistochemical, and molecular homology with cervical mesonephric adenocarcinoma, there are many clinicopathologic features that suggest müllerian derivation, and this is now well established. As research on MLA has accumulated, questions have emerged about optimal practices for the diagnosis of these challenging tumors. In 2022, faculty at M.D. Anderson Cancer Center convened the Mesonephric-like Adenocarcinoma (MLA) Consortium, comprised of international pathologists, gynecologic oncologists, medical oncologists, radiation oncologists, and basic science investigators with expertise in MLA, with the goals to enhance understanding of these tumors, refine diagnostic criteria, improve treatment options, and facilitate research collaborations. An initial review from the consortium was published in 2025, and included diagnostic recommendations from the group’s pathologists. Controversies remain, however, about the morphologic, immunohistochemical, and molecular criteria that should be used to establish a diagnosis of MLA. Herein, the pathologists from the MLA Consortium provide a comprehensive evaluation of the literature on MLA diagnostic criteria, address ongoing controversies in this area, and provide practical guidance for pathologists considering this entity.


  • Napsin-A Expression in Mesonephric and Mesonephric-like Adenocarcinomas: Implications for Distinction From Clear Cell Carcinoma

    by Jelena Mirkovic, Ekaterina Olkhov-Mitsel, Sharon Nofech-Mozes, Oluwole Fadare, W. Glenn FRCPath McCluggage

    Mesonephric adenocarcinoma (MA) and mesonephric-like adenocarcinoma (MLA) are rare gynecological neoplasms that sometimes exhibit morphologic overlap with clear cell carcinoma (CCC), which may lead to diagnostic challenges. Napsin-A is regarded as the most specific immunohistochemical marker of CCC, but its expression in MLA and MA has not been widely investigated. This study investigated the expression of Napsin-A in a series of MAs and MLAs to determine its utility in distinguishing these neoplasms from CCC. The cohort included 32 MLAs arising in the ovary, endometrium, abdominal wall, and sigmoid mesocolon, 13 cervical MLAs, 2 ovarian mesonephric-like carcinosarcomas, and 1 cervical mesonephric carcinosarcoma, with Napsin-A immunohistochemistry performed on whole-slide tissue sections. Napsin-A staining was positive in 17 of 48 cases (35.4%), with focal granular cytoplasmic expression ranging from 1% to 40%. In all, 13/32 (40.6%) MLAs, 2/13 (15.4%) MAs, and 2/3 (66.7%) mesonephric or mesonephric-like carcinosarcomas were positive. Our results demonstrate that Napsin-A is expressed in a significant subset of MLAs and MAs. Given the morphologic and immunohistochemical overlap, this may contribute to misclassification as CCC, especially in cases with ambiguous morphology. Pathologists should be aware of this diagnostic pitfall and employ a panel of markers rather than relying on a single marker.


  • Quantitative diagnosis of amyloid without Congo red staining using polarized light microscopy

    by Owen Lailey, Maria Agustina Alais, Liuhe Wang, Pinki Chahal, David G. Cory, Timothy Khoo, Ekaterina Olkhov-Mitsel, Dusan Sarenac, Dmitry A. Pushin, Jelena Mirkovic

    Amyloidosis is a protein misfolding disease caused by the deposition of large, insoluble aggregates (amyloid fibrils) of protein in a tissue, which has been associated with various conditions, such as lymphoid disorders, Alzheimer’s disease, diabetes mellitus type 2, chronic inflammatory processes, and cancers. Amyloid fibrils are commonly diagnosed by qualitative observation of green birefringence from Congo red-stained biopsy tissue samples under polarized light, a technique that is limited by lack of specificity, dependence on subjective interpretation, and technical constraints. Studies emphasize the utility of quantitative polarized light microscopy (PLM) methodology to diagnose amyloid fibrils in Congo red-stained tissues. However, while Congo red enhances the intrinsic birefringence of amyloid fibrillar structures, there are significant disadvantages, such as the appearance of multiple non-green colors under polarized light and binding to other structures, which may result in misdiagnoses with Congo red dye and inconclusive explanations. In this work, we present an improved PLM methodology for the quantitative detection of amyloid fibrils without requiring Congo red staining. We perform PLM measurements on four tissues: abdominal subcutaneous tissue biopsy, duodenal biopsy, thyroid biopsy, and breast biopsy, both with Congo red stain and hematoxylin and eosin (H&E) stain, and through Fourier analysis, quantify birefringence, birefringent axis orientation, dichroism, optical activity, and relative amyloid density. These results emphasize a quantitative analysis for amyloid diagnosis rooted in Fourier signal harmonics that does not require Congo red dye and paves the way for rapid, simple, and accurate diagnosis of amyloid fibrils.


  • Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics

    by Kari L. Ring, Anne M. Mills, Brooke E. Howitt, Rachel N. Grisham, Elizabeth D. Euscher, Hyun-Soo Kim, Ann H. Klopp, David L. Kolin, W. Glenn McCluggage, Jelena Mirkovic, et al.


  • Open Access

    Quantitative diagnosis of amyloid without Congo red staining using polarized light microscopy

    by Owen Lailey, Maria Agustina Alais, Liuhe Wang, Pinki Chahal, David G. Cory, Timothy Khoo, Ekaterina Olkhov-Mitsel, Dusan Sarenac, Dmitry A. Pushin, Jelena Mirkovic

    Amyloidosis is a protein misfolding disease caused by the deposition of large, insoluble aggregates (amyloid fibrils) of protein in a tissue, which has been associated with various conditions, such as lymphoid disorders, Alzheimer's disease, diabetes mellitus type 2, chronic inflammatory processes, and cancers. Amyloid fibrils are commonly diagnosed by qualitative observation of green birefringence from Congo red stained biopsy tissue samples under polarized light, a technique that is limited by lack of specificity, dependence on subjective interpretation, and technical constraints. Studies emphasize the utility of quantitative polarized light microscopy (PLM) methodology to diagnose amyloid fibrils in Congo red stained tissues. However, while Congo red enhances the intrinsic birefringence of amyloid fibrillar structures, there are significant disadvantages such as the appearance of multiple non-green colors under polarized light and binding to other structures, which may result in misdiagnoses with Congo red dye and inconclusive explanations. In this work, we present an improved PLM methodology for quantitative detection of amyloid fibrils without requiring Congo red staining. We perform PLM measurements on four tissues: abdominal subcutaneous tissue biopsy, duodenal biopsy, thyroid biopsy, and breast biopsy, both with Congo red stain and H\&E stain, and through Fourier analysis quantify birefringence, birefringent axis orientation, dichroism, optical activity, and relative amyloid density. These results emphasize a quantitative analysis for amyloid diagnosis rooted in Fourier signal harmonics that does not require Congo red dye and paves the way for rapid, simple, and accurate diagnosis of amyloid fibrils.

  • STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours

    by Amir Dehghani, Aarti E Sharma, Stephanie E Siegmund, Chrystalle K Carreon, Colin J R Stewart, Fabiola Medeiros, Jelena Mirkovic, Marisa R Nucci, Christopher P Crum, Jason L Hornick, et al.

    Aims: STK11 adnexal tumour is a rare, recently described malignant neoplasm that is associated with Peutz–Jeghers syndrome. [Correction added on 3 October 2024, after first online publication: ‘ST11’ in preceding sentence has been corrected to ‘STK11’ in this version.] It predominantly originates from the para‐adnexal soft tissues and often shows secondary involvement of the fallopian tube and ovary. STK11 adnexal tumours have a broad differential diagnosis due to their variable morphology and non‐specific immunoprofile, and diagnostic confirmation currently requires sequencing to identify an STK11 mutation. We investigate the diagnostic utility of STK11 (LKB1) immunohistochemistry (IHC) in a cohort of STK11 adnexal tumours and morphological mimics.Methods and results: IHC for STK11 was performed on 122 tumours, including 17 STK11 adnexal tumours and 105 morphological mimics (10 female adnexal tumours of Wolffian origin, 22 adult granulosa cell tumours, 10 juvenile granulosa cell tumours, four Sertoli–Leydig cell tumours, two Leydig cell tumours, one Sertoli cell tumour, one steroid cell tumour, four extra‐ovarian sex cord‐stromal tumours, 16 ovarian endometrioid carcinomas, eight tubo‐ovarian high‐grade serous carcinomas, five ovarian mesonephric‐like adenocarcinomas, 14 ovarian carcinosarcomas, five peritoneal malignant mesotheliomas, two pelvic plexiform leiomyomata and one ovarian solid pseudopapillary tumour). All STK11 adnexal tumours showed complete loss of cytoplasmic staining for STK11. All other tumour types showed retained cytoplasmic staining, except for one endometrioid carcinoma with mucinous differentiation which showed complete loss of STK11 expression and a high‐grade serous carcinoma with subclonal loss.Conclusions: STK11 is a highly sensitive and specific immunohistochemical marker for distinguishing STK11 adnexal tumour from its histological mimics, and can obviate the need for confirmatory molecular studies in the appropriate morphological context.


  • Open Access

    Endometrial Carcinosarcomas are Almost Exclusively of p53abn Molecular Subtype After Exclusion of Mimics

    by Jutta M.D. Huvila, Amy M.B.Ch.B Jamieson, Jennifer Pors, Lynn Hoang, Jelena Mirkovic, Dawn Cochrane, Jessica N. McAlpine, C. Blake Gilks

    Summary: Our aim was to assess the molecular subtype(s) and perform a detailed morphologic review of tumors diagnosed as carcinosarcoma in a population-based cohort. Forty-one carcinosarcomas were identified from a cohort of 973 endometrial carcinomas diagnosed in 2016. We assessed immunostaining and sequencing data and undertook expert pathology reviews of these cases as well as all subsequently diagnosed (post-2016) carcinosarcomas of no specific molecular profile (NSMP) molecular subtype (n=3) from our institutions. In the 2016 cohort, 37 of the 41 carcinosarcomas (91.2%) were p53abn, 2 (4.9%) were NSMP, and 1 each (2.4%) were POLEmut and mismatch repair deficiency molecular subtypes, respectively. Of the 4 non-p53abn tumors on review, both NSMP tumors were corded and hyalinized (CHEC) pattern endometrioid carcinoma, the mismatch repair deficiency tumor was a grade 1 endometrioid carcinoma with reactive stromal proliferation, and the POLEmut tumor was grade 3 endometrioid carcinoma with spindle cell growth, that is, none were confirmed to be carcinosarcoma on review. We found 11 additional cases among the 37 p53abn tumors that were not confirmed to be carcinosarcoma on the review (3 undifferentiated or dedifferentiated carcinomas, 5 carcinomas with CHEC features, 2 carcinomas showing prominent reactive spindle cell stroma, and 1 adenosarcoma). In the review of institutional cases reported as NSMP carcinosarcoma after 2016, 3 were identified (1 adenosarcoma and 2 mesonephric-like adenocarcinoma on review). In this series, all confirmed endometrial carcinosarcomas were p53abn. The finding of any other molecular subtype in a carcinosarcoma warrants pathology review to exclude mimics.


  • Open Access

    Genomic profiling of dedifferentiated endometrial carcinomas arising in the background of high‐grade carcinoma: a targeted next‐generation sequencing study

    by Ekaterina Olkhov‐Mitsel, Aurelia Busca, Carlos Parra‐Herran, Yutaka Amemiya, Sharon Nofech‐Mozes, Bojana Djordjevic, Marisa R Nucci, Arun Seth, Jelena Mirkovic

    AimsOur understanding of dedifferentiated endometrial carcinoma (DEC), a rare and aggressive malignancy, mainly reflects undifferentiated carcinomas (UC) arising in the setting of low-grade endometrial cancer (DEC-LG). However, cases of UC arising in the setting of high-grade EC (DEC-HG) have been noted in the literature. Our knowledge of the genomics of DEC-HG is limited. To characterise the molecular landscape of DEC-HC, targeted genomic sequencing and immunohistochemical analysis was carried out on seven DEC-HG and four DEC-LG. Methods and resultsDEC-HG and DEC-LG, including undifferentiated and differentiated components, both showed a similar frequency and spectrum of mutations. ARID1A mutations were identified in 6/7 (86%) DEC-HG and 4/4 (100%) DEC-LG, while SMARCA4 mutations were present in 4/7 (57%) DEC-HG and in 1/4 (25%) DEC-LG. Concurrent SMARCA4/BRG1 protein loss by immunohistochemistry was observed in 3/4 and 1/1 SMARCA4 mutated DEC-HG and DEC-LG, respectively. Neither genomic alterations nor protein loss in SMARCB1/INI1 were observed in any of our cases. TP53 mutations were detected in 4/7 (57%) DEC-HG and in 2/4 (50%) DEC-LG, while mutation-pattern p53 immunohistochemistry expression was observed in 2/7 (29%) DEC-HG and none of the DEC-LG. MLH1 mutations were observed in 1/7 (14%) DEC-HG and 1/4 (25%) DEC-LG. MSH2 and MSH6 mutations were each detected in 1/7 (14%) DEC-HG, but neither was associated with corresponding loss of protein expression. ConclusionThe findings support expanding the definition of DEC to include DEC-HG, a previously under-recognised phenomenon with genomic similarities to DEC-LG.